Piper Sandler has reaffirmed its Overweight rating on Structure Therapeutics (NASDAQ: GPCR), maintaining a $93.00 price target for the company's stock.
The endorsement follows comparative analysis of clinical study results for an oral GLP-1 class drug, TERN-601, which is not part of Structure Therapeutics' portfolio.
The study showed that patients achieved up to 4.9% placebo-adjusted weight loss after 28 days, a result comparable to that of Structure Therapeutics' GSBR-1290.
The analysis highlighted GSBR-1290's more favorable gastrointestinal tolerability profile, with lower rates of vomiting and constipation compared to TERN-601 in a similar patient group.
These findings come as Structure Therapeutics anticipates the release of 36-week Phase 2b topline data for GSBR-1290 in the fourth quarter of 2025.
Structure Therapeutics is noted for its progress in developing a comprehensive portfolio of oral small-molecule drugs targeting multiple mechanisms of action. The company is expected to nominate its amylin dual-agonist candidate in the fourth quarter of 2024.
This class of drugs has been clinically validated by other companies' research, indicating a significant opportunity for Structure Therapeutics to capitalize on this mechanism of action.
In other recent news, Structure Therapeutics has seen several significant developments. The pharmaceutical company announced the appointment of Angus Russell to its Board of Directors, serving as a Class I director until the 2027 Annual Meeting of Shareholders.
Russell's appointment was followed by the election of Sharon Tetlow as a Class I Director and the appointment of Ted W. Love, M.D. to the Audit Committee.
The company also reported promising results from its Phase 2a trial of oral therapeutic GSBR-1290, showing significant weight loss and manageable adverse events. The company's confidence is echoed by BMO Capital Markets and JPMorgan (NYSE:JPM), both maintaining positive ratings on the company's potential.
Additionally, Structure Therapeutics disclosed plans for an underwritten public offering of 8 million American Depositary Shares (ADSs), with Goldman Sachs (NYSE:GS) & Co. LLC, Morgan Stanley (NYSE:MS), Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets as joint book-running managers. This offering is subject to market conditions.
InvestingPro Insights
As Structure Therapeutics (NASDAQ:GPCR) gears up for critical clinical milestones, real-time data from InvestingPro provides a snapshot of the company's financial health and market performance. With a market capitalization of $2.01 billion, the company's financial status is underscored by a significant metric: it holds more cash than debt on its balance sheet. This positions Structure Therapeutics favorably in terms of financial stability as it moves forward with its clinical trials.
On the performance front, despite recent volatility with the stock taking a notable hit over the last week, showing a 7.75% decline, analysts have shown confidence by revising their earnings upwards for the upcoming period. This suggests a belief in the company's potential to bounce back and progress positively. Additionally, Structure Therapeutics has liquid assets that exceed its short-term obligations, providing further assurance of its ability to meet immediate financial needs.
For those seeking more in-depth analysis, InvestingPro offers additional tips to help evaluate Structure Therapeutics' prospects. Currently, there are 5 more InvestingPro Tips available at InvestingPro, which can provide investors with a more comprehensive understanding of the company's outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.